Background: Despite the fact that clinical guidelines forbid this practice, BZDs and Z medications are still used for longer than the time of prescription in current clinical practice. This practice results in adverse effects. The purpose of this research was to determine whether or not it would be possible to stop giving BZDs and Z medicines to patients who had been misusing these medications for far longer than the allotted time frame. This study also looked into the Sleeping well (QoS) and financial savings that patients who were deprescribed experienced. Methods: A prospective interventional study was conducted at the Psychiatric Department in both the inpatient and outpatient settings. Over the course of the study’s Twelve -month recruitment period, 109 patients in all were enrolled, which was based on the inclusion criteria. Following a discussion with the prescribing psychiatrist, suggested that unsuitable BZD and Z-drugs users begin the process of deprescribing their medications. After they were taken off their medications, For the next 30 days, twice a month the patients were examined. To do the QoS analysis, the Pittsburg Sleep Quality Index (PSQI) was used as a measurement. Before and after the intervention, the total cost of medications that each patient had to pay each month was calculated and compared between the two groups. Results: Following the intervention, 41 (37.61%) BZD users had their prescriptions for the drug revoked, which meant that their dose was either reduced 6 (5.5%), completely discontinued 28 (25.68%), or use a prescription for is opus sit (SOS) BZD 7 (6.4%). 43 patients (39.44.36%) continued BZDs as prescribed by the algorithm. The BZD that was deprescribed the most commonly was clonazepam 34 (82.92%). Patients’ quality of life and the deprescription of BZDs were linked, according to p-value (<0.05). After deprescribing BZDs, a statistically significant cost reduction was seen (Z=5.6244, p=<0.001). Conclusion: Deprescribing BZDs was linked to a decrease in consumption; applying deprescribing procedures to inappropriate BZD users is doable, enhances service quality, and has positive financial implications. Highlights: (1) This is the study to investigate whether or not it would be possible to stop administering BZDs. (2) Patients who use BZDs (clonazepam, alprazolam, zolpidem) for an unnecessarily long period of time or for longer than the length that was prescribed are candidates for deprescribing.

Background: Despite the fact that clinical guidelines forbid this practice, BZDs and Z medications are still used for longer than the time of prescription in current clinical practice. This practice results in adverse effects. The purpose of this research was to determine whether or not it would be possible to stop giving BZDs and Z medicines to patients who had been misusing these medications for far longer than the allotted time frame. This study also looked into the Sleeping well (QoS) and financial savings that patients who were deprescribed experienced. Methods: A prospective interventional study was conducted at the Psychiatric Department in both the inpatient and outpatient settings. Over the course of the study’s Twelve -month recruitment period, 109 patients in all were enrolled, which was based on the inclusion criteria. Following a discussion with the prescribing psychiatrist, suggested that unsuitable BZD and Z-drugs users begin the process of deprescribing their medications. After they were taken off their medications, For the next 30 days, twice a month the patients were examined. To do the QoS analysis, the Pittsburg Sleep Quality Index (PSQI) was used as a measurement. Before and after the intervention, the total cost of medications that each patient had to pay each month was calculated and compared between the two groups. Results: Following the intervention, 41 (37.61%) BZD users had their prescriptions for the drug revoked, which meant that their dose was either reduced 6 (5.5%), completely discontinued 28 (25.68%), or use a prescription for is opus sit (SOS) BZD 7 (6.4%). 43 patients (39.44.36%) continued BZDs as prescribed by the algorithm. The BZD that was deprescribed the most commonly was clonazepam 34 (82.92%). Patients’ quality of life and the deprescription of BZDs were linked, according to p-value (<0.05). After deprescribing BZDs, a statistically significant cost reduction was seen (Z=5.6244, p=<0.001). Conclusion: Deprescribing BZDs was linked to a decrease in consumption; applying deprescribing procedures to inappropriate BZD users is doable, enhances service quality, and has positive financial implications. Highlights: (1) This is the study to investigate whether or not it would be possible to stop administering BZDs. (2) Patients who use BZDs (clonazepam, alprazolam, zolpidem) for an unnecessarily long period of time or for longer than the length that was prescribed are candidates for deprescribing.